What is QMSR vs QSR? Understanding The FDA Final Rule and ISO 13485 Harmonization
The Quality Management System Regulation (QMSR) is the U.S. Food and Drug Administration’s (FDA) new rule replacing the Quality System Regulation (QSR) for medical devices. Finalized in February 2024, QMSR updates 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, aligning U.S. quality system requirements with the internationally recognized medical device standard while retaining certain FDA-specific obligations. The regulation will be enforced beginning February 2, 2026.
QMSR represents a significant step toward global regulatory harmonization and a more streamlined, risk-based approach to quality management. As part of this transition, the FDA is withdrawing the legacy QSIT inspection technique and introducing a QMSR-aligned inspection model, expanding the scope of quality system records that may be reviewed during FDA inspections.
This article explains what QMSR is, why the FDA introduced it, how it aligns with ISO 13485, and how quality system expectations and FDA inspections will change ahead of enforcement. It also outlines what manufacturers should focus on during the transition period.
What is QMSR?
The Quality Management System Regulation (QMSR) is the FDA’s updated quality system rule for medical devices. It replaces the Quality System Regulation (QSR) by updating 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, aligning U.S. quality system requirements with the internationally recognized medical device standard.
Under QMSR, most legacy QSR provisions are replaced with ISO 13485 clauses, alongside FDA-specific requirements needed to comply with U.S. law. The goal of QMSR is to harmonize quality management expectations globally while continuing to ensure the safety and effectiveness of medical devices marketed in the United States.
When does QMSR take effect?
QMSR enforcement date and transition period
QMSR will be enforced beginning February 2, 2026. Until that date, medical device manufacturers must continue complying with the existing Quality System Regulation under 21 CFR Part 820.
The FDA published the QMSR final rule in February 2024, establishing a transition period intended to give manufacturers time to assess gaps, update documentation, train personnel, and adjust quality systems before enforcement begins.
Why did the FDA introduce QMSR?
The FDA introduced QMSR to promote international harmonization of medical device quality system requirements. By aligning U.S. regulations with ISO 13485, the FDA aims to reduce regulatory duplication for manufacturers operating globally while maintaining robust oversight of device quality.
QMSR also reflects a shift toward system-based quality management, emphasizing lifecycle risk management, leadership accountability, and continuous improvement rather than prescriptive documentation structures.
How QMSR aligns with ISO 13485:2016
Is QMSR the same as ISO 13485?
QMSR is not identical to ISO 13485. While the FDA adopted the structure and core requirements of ISO 13485:2016, QMSR incorporates additional provisions to ensure compliance with U.S. statutory and regulatory requirements, including FDA-specific expectations related to labeling, records access, and enforcement.
Manufacturers aligned with ISO 13485 will still need to confirm that their quality systems meet all applicable QMSR requirements.
Do manufacturers need ISO 13485 certification to comply with QMSR?
No. ISO 13485 certification is not required to comply with QMSR for manufacturers that market devices only in the United States. However, manufacturers must align their quality management systems with ISO 13485 requirements as incorporated into QMSR.
ISO 13485 certification may still be required for manufacturers placing devices on other markets, such as the European Union, Canada, or Australia.
Regulatory changes introduced by QMSR
QMSR introduces several notable changes compared to the legacy Quality System Regulation. The table below summarizes the most significant regulatory and inspection-related differences between QSR and QMSR.
QMSR vs QSR: summary of key changes
| Area | Under QSR (legacy approach) | Under QMSR (effective Feb 2, 2026) |
| Regulatory framework | FDA-specific Quality System Regulation under 21 CFR Part 820 | Alignment of 21 CFR Part 820 with ISO 13485:2016 |
| Regulatory status | Longstanding FDA quality system regulation | Final rule published February 2024; enforcement begins February 2, 2026 |
| Relationship to ISO standards | ISO 13485 not formally incorporated | ISO 13485 incorporated by reference, with FDA-specific additions |
| Terminology | FDA-specific terms such as DMR, DHR, and DHF | ISO 13485 terminology replaces legacy FDA terms |
| Quality system structure | Prescriptive, subsystem-based requirements | System-based quality management aligned with ISO principles |
| Records subject to FDA inspection | Certain records are typically exempt | The FDA may inspect records previously exempt |
| Risk management | Addressed primarily in design and development | Embedded across the full device lifecycle |
| Inspection model | QSIT inspection technique | QMSR-aligned, system-based FDA inspections |
| Inspection focus | Discrete subsystem compliance | How quality processes interact across the organization |
| ISO 13485 certification | Not required | Still not required for U.S.-only manufacturers |
| Global alignment | Limited | Increased alignment with other regulatory authorities |
Terminology and quality system documentation
QMSR adopts ISO terminology and removes legacy FDA-specific document terms such as Device Master Record (DMR), Device History Record (DHR), and Design History File (DHF). Quality system documentation will need to align with ISO 13485 concepts.
What this means
Documentation should reflect ISO 13485 terminology and structure, with legacy FDA terms appropriately mapped or retired.
What manufacturers can do
- Cross-reference terminology, mapping legacy FDA terms to ISO 13485 concepts
- Update SOPs and templates to use ISO-aligned language consistently
- Ensure teams are trained on updated terminology for audits and inspections
Records control and documentation access
QMSR introduces updated records control requirements aligned with ISO 13485. FDA may request access to certain records aligned with ISO 13485 expectations, including management review and supplier controls, subject to inspection discretion.
What this means
Previously exempt records must now be formally controlled and inspection-ready.
What manufacturers can do
- Bring these records into the formal records control system
- Define retention periods, approval workflows, and access controls
- Conduct internal audits assuming these records may be reviewed by FDA
Labeling and packaging requirements under QMSR
While QMSR aligns with ISO 13485, the FDA retains its authority over labeling and packaging requirements.
What this means
ISO alignment alone is not sufficient for FDA labeling and packaging compliance.
What manufacturers can do
- Identify labeling and packaging controls that are FDA-specific
- Verify controls meet both ISO and QMSR requirements
- Ensure labeling records are traceable and inspection-ready
Risk management across the product lifecycle
QMSR reinforces risk management as a lifecycle activity consistent with ISO 13485 expectations.
What this means
Risk management must be maintained and demonstrable across the full device lifecycle.
What manufacturers can do
- Extend risk management beyond design into manufacturing and post-market activities
- Link risk outputs to CAPA, change control, and management review
- Maintain traceability between risks and mitigation actions
How FDA inspections will change under QMSR
End of the QSIT inspection technique
The FDA is withdrawing the Quality System Inspection Technique (QSIT), which historically structured inspections around four major subsystems.
What this means
Inspection preparation should no longer be based on QSIT checklists.
What manufacturers can do
- Shift to a system-wide inspection mindset
- Prepare teams to explain how quality processes interact
QMSR-aligned, system-based FDA inspections
FDA inspections will follow a QMSR-aligned, system-based approach that mirrors ISO-style quality management expectations.
What this means
Inspections are expected to be broader and more integrated.
What manufacturers can do
- Conduct mock inspections using process walkthroughs
- Confirm readiness for records not previously reviewed by FDA
FDA guidance supporting QMSR implementation
FDA draft guidance on QMSR and premarket submissions
The FDA has issued draft guidance providing additional context on how QMSR principles may be applied during premarket submission reviews.
What this means
Premarket reviews are expected to increasingly reflect QMSR expectations.
What manufacturers can do
- Review draft guidance alongside submission processes
- Ensure quality system documentation supports submission claims
What QMSR means for different types of manufacturers
Manufacturers with QSR but not ISO 13485
Manufacturers should familiarize teams with ISO 13485 and identify gaps between existing practices and QMSR expectations.
Manufacturers with ISO 13485 but not FDA QSR/QMSR
Manufacturers planning to market devices in the U.S. should confirm their quality systems address FDA-specific QMSR requirements beyond ISO certification.
Manufacturers without an established quality management system
Manufacturers should consider ISO 13485 as a foundational framework to support scalable compliance and QMSR readiness.
How to prepare for QMSR before February 2026
With the QMSR final rule published and enforcement approaching, preparation should now focus on practical readiness activities rather than understanding the regulation itself.
QMSR readiness checklist
The checklist below summarizes the core readiness actions discussed throughout this article:
- Confirm QMSR scope and enforcement timing
- Perform a QMSR and ISO 13485 gap assessment
- Align documentation structure and terminology
- Bring newly inspectable records under formal control
- Confirm risk management is applied across the lifecycle
- Prepare for system-based FDA inspections
- Train personnel on QMSR-related changes
Using the transition period to address these areas can help ensure quality systems are aligned with QMSR expectations and inspection-ready ahead of enforcement.
Summary: What is QMSR and how will the FDA changes impact medical device quality systems?
This article has outlined what QMSR is, why the FDA introduced it, and how it will change medical device quality system expectations and FDA inspections. The key points to be aware of are:
- QMSR replaces the FDA Quality System Regulation by aligning 21 CFR Part 820 with ISO 13485:2016
- The final rule was published in February 2024, with enforcement beginning February 2, 2026
- Quality systems must align with ISO 13485 requirements, without mandatory ISO certification for U.S.-only manufacturers
- QMSR expands FDA inspection access to records previously exempt under QSR
- FDA inspections will move from QSIT to system-based, ISO-aligned approaches
How Apotech can support your QMSR transition
Apotech supports medical device manufacturers in preparing for QMSR through gap assessments, quality system alignment, documentation review, and inspection readiness activities.
For more information on how we can help, speak to one of our experts today.
QMSR FAQs
The purpose of QMSR is to align FDA medical device quality system requirements with ISO 13485 to promote global harmonization, improve consistency in quality oversight, and modernize FDA’s regulatory framework while maintaining patient safety.
QSR is the legacy FDA quality system regulation, while QMSR replaces it by incorporating ISO 13485 requirements into U.S. law. QMSR modernizes structure, terminology, and inspection expectations while retaining FDA-specific regulatory authority.
Under ISO 13485 and QMSR, a QMS includes management responsibility, resource management, product realization, and measurement, analysis, and improvement.
An FDA final rule is a legally binding regulation issued after public comment. In this case, the QMSR final rule updates 21 CFR Part 820 and establishes the regulatory framework that will be enforced beginning February 2, 2026.
FDA inspections generally include pre-approval inspections, routine surveillance inspections, for-cause inspections, and compliance follow-up inspections. These inspection types will continue under QMSR using an updated, system-based approach.
ISO 9001 is a general quality management standard applicable across industries, while ISO 13485 is specific to medical devices and emphasizes regulatory compliance and risk management throughout the product lifecycle.